

Pilocytic astrocytoma (PA) is the most common paediatric brain tumour, and there are few medical therapies available to those patients for whom surgery is not curative. However, it has been difficult to design targeted PA therapies because the cellular mechanisms that lead to the cancer are incompletely understood, and there is no animal model of the disease.
Recent work has suggested that activation of a particular cell signalling pathway may be required for PA formation, and mutations in one gene in that pathway, a kinase called BRAF, are found in more than half of all PA cases. In this paper, Peter Lichter and colleagues at the German Cancer Research Centre, in Heidelberg, Germany investigated how BRAF protein contributes to PA formation. They found that expression of just part of the BRAF protein in mice was sufficient to induce the formation of brain tumours that closely resembled the human disease. They are hopeful that this new animal model helps define the molecular processes that lead to PA, and may be useful in the design and testing of new therapeutics.
The Australian E-Health Research Centre joins Open Health Tools Foundation
Research identifies mechanism behind mind-body connection
New molecular tag identifies bone and tooth minerals
The coming epidemic of type 2 diabetes in young adults